Mythili Koneru

Dr. Koneru is charged with overseeing all clinical development and medical affairs activities at Legend Biotech. Dr. Koneru assumed the role with extensive experience and expertise in the field of immunotherapy and cell therapy.

Before joining Legend, she was the Chief Medical Officer of Marker Therapeutics, leading development of cellular therapies and peptide vaccines in its immune-oncology portfolio. As Associate Vice President of Immuno-Oncology at Eli Lilly, Mythili designed early-stage clinical trials for hematologic malignancies and solid tumors, and she was instrumental in developing clinical trial protocols, serving as medical lead for trial conduct. Dr. Koneru also served as Senior Medical Director of Early Phase Clinical Development at Eli Lilly.

Prior to Eli Lilly, Dr. Koneru was an oncology fellow in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies for both leukemia and solid tumors in early phase clinical trials.

Dr. Koneru earned her bachelor’s degree in biology from the University of Chicago, her doctorate degree in Tumor Biology from New York University, and her medical degree from Robert Wood Johnson Medical School.